
RNAC Stock Forecast & Price Target
RNAC Analyst Ratings
Bulls say
Cartesian Therapeutics, Inc. is showing substantial promise due to positive Phase 2b data indicating sustained clinically meaningful improvements, with a notable average reduction of 4.8 in MG-ADL scores at 12-month dosing intervals. Furthermore, the differentiated profile of Descartes-08 supports its potential for broader patient uptake, particularly in biologic-naive patients, while maintaining a clean safety profile over time with no significant adverse events reported. The firm's proprietary ImmTOR immune tolerance platform, combined with strong biomarker data demonstrating effective immune modulation, underscores a solid foundation for future growth and market penetration within the biopharmaceutical sector.
Bears say
Cartesian Therapeutics Inc. experienced a decline in cash, cash equivalents, and restricted cash from $162.1 million in the second quarter of 2025 to $145.1 million in the third quarter of 2025, indicating significant operational spending as the Phase 3 program for myasthenia gravis ramps up. The company’s market capitalization is under $200 million, leading to a notably low enterprise value of approximately $50 million, which reflects investors' skepticism regarding the value of its lead asset, Descartes-08, in myasthenia gravis despite its regulatory designations. Furthermore, with a revised terminal growth rate expectation cut from 3% to 1%, Cartesian Therapeutics faces challenges in capturing market interest amid unfavorable perceptions of current treatment options and patient burden.
This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNAC Analyst Forecast & Price Prediction
Start investing in RNAC
Order type
Buy in
Order amount
Est. shares
0 shares